Electrospinning has emerged as a transformative platform for fabricating biomimetic scaffolds in tissue engineering, particularly for creating functional vascular constructs. By producing nanofibrous meshes that replicate the structural and biochemical complexity of the native extracellular matrix (ECM), this technique addresses critical needs in regenerative medicine—from small-diameter grafts for bypass surgery to microvascular networks for organ engineering. This article provides an in-depth examination of electrospinning as a method for creating vascular tissue constructs, covering the underlying technology, material selection, scaffold design parameters, current research frontiers, and the road to clinical implementation.

Understanding Electrospinning Technology

Electrospinning is a versatile, electrically driven fiber production process. In its simplest configuration, a polymer solution or melt is extruded through a spinneret under a high electric field (typically 10–30 kV). The charged jet elongates, undergoes bending instabilities, and rapidly solidifies as the solvent evaporates, depositing continuous fibers onto a grounded collector. The resulting nonwoven mat possesses fiber diameters ranging from nanometers to a few micrometers, offering a high surface-to-volume ratio and tunable porosity. Critical process parameters include applied voltage, solution concentration and conductivity, flow rate, and distance between the needle and collector. Adjusting these variables allows precise control over fiber morphology, alignment, and mechanical properties, making electrospinning highly customizable for vascular applications.

While conventional electrospinning produces random fiber orientations, advanced variants such as rotating mandrel collectors or parallel electrodes enable the creation of highly aligned fibers that mimic the circumferential orientation of smooth muscle cells (SMCs) in arterial walls. Coaxial and emulsion electrospinning techniques further allow the formation of core-shell fibers, enabling sustained release of growth factors or antibiotics. Melt electrospinning, which eliminates toxic solvents, is increasingly explored for producing thicker, hierarchical scaffolds suitable for load-bearing vascular grafts.

Designing Scaffolds for Vascular Grafts

The ideal vascular scaffold must satisfy a stringent set of requirements: mechanical strength and compliance matching native arteries, porosity sufficient for mass transport and cell infiltration, hemocompatibility, and the ability to support rapid endothelialization. Electrospinning can address these criteria through careful selection of materials, fiber architecture, and post-processing treatments. The scaffold must also resist thrombosis and intimal hyperplasia, especially in small-diameter grafts (less than 6 mm), where failure rates remain high.

Natural Polymers

  • Collagen: The primary ECM protein in blood vessels. Electrospun collagen retains bioactive motifs that promote endothelial cell adhesion and proliferation. However, its weak mechanical properties necessitate crosslinking (e.g., using EDC/NHS or genipin).
  • Gelatin: Denatured collagen that is easier to process and less expensive. Often blended with synthetic polymers to improve stability and strength.
  • Elastin: Provides elasticity. Recombinant or tropoelastin is electrospun to mimic the recoil of arterial walls.
  • Fibrinogen: Used for its inherent bioactivity and rapid degradation; can be crosslinked to form stable fibrin microfibers.

Synthetic Biodegradable Polymers

  • Polycaprolactone (PCL): Widely studied due to its slow degradation rate (2–3 years) and good mechanical properties. Often blended with natural polymers to improve bioactivity.
  • Poly(lactic-co-glycolic acid) (PLGA): Tunable degradation rates; can be formulated to match the remodeling timeline of host tissue.
  • Polyurethanes (PU): Offer superior elasticity and compliance, closely matching native blood vessel properties. Certain segmented polyurethanes are hemocompatible.
  • Poly(ester urethane)urea (PEUU): Combines biodegradability with elastomeric behavior; used in vascular scaffolds tested in vivo.

Blends and composites—such as PCL/collagen or PLGA/elastin—are frequently employed to balance mechanical integrity with biological signaling. The incorporation of bioactive molecules, including vascular endothelial growth factor (VEGF), heparin, or nitric oxide donors, can be achieved through electrospinning blended solutions or coaxial procedures, providing local controlled release to modulate the host response.

The Role of Fiber Alignment and Architecture

Vascular tissue is highly organized: the intima presents a quiescent endothelial monolayer; the media contains circumferentially oriented SMCs and elastic laminae; the adventitia comprises longitudinally oriented collagen fibers. Electrospinning can recreate these anisotropic structures. Collecting fibers onto a rotating mandrel (up to 5000 rpm) produces aligned fibers in the circumferential direction. By sequentially depositing layers with different orientations or by using customized collectors, a bilayered or trilayered graft can be fabricated. For example, an inner layer of aligned fibers mimics the media, while an outer randomly oriented layer provides mechanical integrity and promotes adventitial cell infiltration.

Multilayered constructs also allow differential pore sizes: a dense inner layer prevents blood leakage and platelet adhesion, while a more porous outer layer supports neovascularization and host cell migration. Recent advances in near-field electrospinning and melt electro-writing enable the programmed deposition of fibers with micron-scale accuracy, creating predetermined microarchitectures that guide cell alignment and matrix deposition.

Incorporating Bioactive Molecules

Beyond structural mimicry, electrospun scaffolds can serve as drug delivery systems. Bioactive agents are either incorporated directly into the polymer solution before spinning, attached to the fiber surface post-synthesis, or encapsulated in core-shell fibers. Key examples include:

  • VEGF: Stimulates endothelial cell migration and tube formation. Controlled release prevents potential angiogenesis-related complications.
  • Heparin: Immobilized onto fiber surfaces to reduce thrombogenicity and bind growth factors like fibroblast growth factor (FGF).
  • Antibiotics: Such as gentamicin or vancomycin, to prevent graft infection.
  • Nitric oxide (NO) donors: Promote vasodilation and inhibit platelet activation.
  • Stromal cell-derived factor-1α (SDF-1α): Recruits endothelial progenitor cells to accelerate in situ endothelialization.

Surface modification techniques—including plasma treatment, chemical grafting, or layer-by-layer assembly—can further enhance cell adhesion and bioactivity without altering the bulk mechanical properties. The ability to present multiple signals in a spatiotemporal manner is a key advantage of electrospun scaffolds for functional graft regeneration.

Current Advances and Emerging Strategies

Electrospinning continues to evolve in combination with other fabrication methods. Hybrid electrospinning-3D printing systems allow the fabrication of large, hierarchical constructs where 3D-printed lattice structures provide macroporosity, while electrospun nanofibers fill the interstices with nano-scale topography. This hybrid approach addresses a major limitation of electrospinning—dense fiber packing that restricts cellular infiltration and nutrient diffusion.

Another promising direction is in situ electrospinning, where fibers are deposited directly onto a defect site using a handheld device during surgery. This technique, still in preclinical stages, could enable personalized, immediate repair of vascular injuries. Researchers have also developed stimuli-responsive electrospun scaffolds that change porosity or release drugs in response to pH, temperature, or enzymatic activity associated with inflammation or infection.

The use of decellularized ECM-derived materials (e.g., from porcine carotid arteries) in electrospinning has gained traction. After decellularization, the ECM is processed into a soluble form that can be electrospun into scaffolds retaining native growth factors and structural proteins, enhancing the regenerative potential.

Challenges in Clinical Translation

Despite considerable progress, several barriers prevent the widespread clinical use of electrospun vascular grafts. Mechanical mismatch remains a critical issue: many electrospun scaffolds are either too stiff (leading to compliance mismatch and intimal hyperplasia) or too weak (liable to rupture under arterial pressure). Strategies to overcome this include blending with elastomeric polymers, post-spinning crosslinking, or incorporating reinforcing meshes.

Thrombosis and Infection

Small-diameter grafts (less than 4 mm) are particularly prone to thrombosis due to low flow rates. While heparin immobilization and endothelial cell seeding reduce clot formation, achieving a confluent endothelium in vivo remains elusive. Infection, especially with Gram-positive bacteria like Staphylococcus aureus, is a further concern. Antibiotic elution or silver nanoparticle incorporation are active areas of research.

Scalability and Sterilization

The batch nature of electrospinning limits throughput. Industrial-scale production requires multi-jet or needleless systems that maintain fiber uniformity. Sterilization methods (e.g., ethylene oxide, gamma irradiation, or supercritical CO₂) must not degrade the polymer or bioactivity. Regulatory approval demands rigorous characterization of fiber diameter distribution, degradation profile, and biocompatibility according to ISO 10993 standards.

Preclinical and Clinical Studies

Many electrospun vascular grafts have been evaluated in animal models, including rats, rabbits, sheep, and non-human primates. Results are encouraging for certain compositions: for example, a bilayered PCL/collagen graft showed patency rates comparable to autologous vein grafts in a sheep carotid artery model at 6 months. Several clinical trials have begun for electrospun vascular patches and grafts, primarily in the context of hemodialysis access and peripheral arterial disease. Early outcomes indicate good handling and low infection rates, but long-term data on endothelialization and mechanical stability are still being collected.

Future Outlook

The future of electrospinning for vascular tissue engineering lies in personalization and integration. Advances in patient-specific imaging and computational modeling will enable the design of grafts with tailored geometry and compliance. Coupled with bioreactor conditioning—where seeded scaffolds are exposed to cyclic stretch and shear stress—electrospun constructs can be matured into more physiologically relevant grafts prior to implantation.

Research into smart biomaterials that respond to enzymatic remodeling or release therapeutics on demand will further improve outcomes. The combination of electrospinning with induced pluripotent stem cells (iPSCs) or patient-derived endothelial cells could eliminate immune rejection. Moreover, the development of off-the-shelf, acellular electrospun grafts that recruit host cells via bioactive cues represents a commercially viable pathway.

As the field moves toward the clinic, collaboration between engineers, biologists, and clinicians will be essential to address the remaining technical and regulatory challenges. With sustained innovation, electrospinning is poised to revolutionize the production of vascular grafts, offering a scalable and tunable platform for restoring blood flow in patients with cardiovascular disease, trauma, or congenital defects.